A unique resource on glioma leverages advances and firsthand insights to enact meaningful change Glioblastoma (GBM) or glioma is an extremely aggressive and malignant brain tumor, with cell infiltration, rapid invasion, and a high frequency of relapse. The Glioma Book by neurosurgeon Michael Sughrue is a highly personal book — a culmination of two years of writing and more than 1,000 surgeries. It presents a unique viewpoint with the potential to transform the traditional paradigm that too often informs treatment of this universally fatal brain tumor. The book reinterprets the role of the cerebrum and sub-cortex, leverages scientific advances to improve cytoreduction and reduce neurological deficits, and challenges the myth of the "inoperable" glioma. This is the first step-by-step technical guide focused on aggressively resecting different types of gliomas. The book is logically organized, starting with a foundation of fundamental knowledge, then progressing to practical applications. Chapters focus on the skills necessary to perform glioma surgery, specific techniques, and systematic approaches to gliomas in different brain regions. Numerous case examples illuminate concepts introduced earlier in the book and explain how to perform these procedures About 30 high quality videos posted online provide insightful procedural guidance The role of connectomic imaging in visualizing the cerebrum, and other innovative techniques including awake brain mapping and diffusion tensor tractography Neurosurgeons who embrace the concepts in this book will realize they can change the glioma treatment paradigm. Continually improving techniques and viewing a glioma diagnosis as a battle for a patient's life, rather than an exercise in inevitable failure can impart progress in treating this devastating disease.

This book covers physiologic, metabolic and molecular imaging for gliomas. Gliomas are the most common primary brain tumors. Imaging is critical for glioma management because of its ability to noninvasively define the anatomic location and extent of disease. While conventional MRI is used to guide current treatments, multiple studies suggest molecular features of gliomas may be identified with noninvasive imaging, including physiologic MRI and amino acid positron emission tomography (PET). These advanced imaging techniques have the promise to help elucidate underlying tumor biology and provide important information that could be integrated into routine clinical practice. The text outlines current clinical practice including common scenarios in which imaging interpretation impacts patient management. Gaps in knowledge and potential areas of advancement based on the application of more experimental imaging techniques will be discussed. In reviewing this book, readers will learn: current standard imaging methodologies used in clinical practice for patients undergoing treatment for glioma and the implications of emerging treatment modalities including immunotherapy the theoretical basis for advanced imaging techniques including diffusion and perfusion MRI, MR spectroscopy, CEST and amino acid PET the relationship between imaging and molecular/genomic glioma features incorporated in the WHO 2016 classification update and the potential application of machine learning about the recently adopted and FDA approved standard brain tumor protocol for multicenter drug trials of the gaps in knowledge that impede optimal patient management and the cutting edge imaging techniques that could address these deficits

This book presents the latest research pertaining to the diagnosis, therapy and management of diffuse low-grade gliomas (DLGG) in adults, with a particular focus on the path towards individualised therapy for this kind of tumour. Recent research on the natural history of DLGGs and their interaction with the brain has led to new diagnostic and therapeutic strategies which increase survival and quality of life of the patient, and these methods are described in this book.

New Techniques for Management of 'Inoperable' Gliomas radically challenges the assumption that certain gliomas cannot be removed with modern techniques, contesting stereotypical thinking and establishing new paradigms in the field. Gliomas are primary brain tumors which are often fatal. Recent data has demonstrated that despite the fact that surgery cannot cure gliomas, patient survival is substantially improved by removing as much of the tumor as possible. This fact has raised the imperative that neurologists try to improve techniques to bring surgical resection to as many patients as possible. This book brings new insights and technologies to the forefront, giving hope to patients. - Provides the first comprehensive book to discuss techniques for removing gliomas that are traditionally deemed 'inoperable' - Presents a great reference tool that challenges stereotypical thinking by offering techniques by innovative surgeons - Includes chapters that are organized by different glioma types and surgery/techniques

This book constitutes revised selected papers from the Third International MICCAI Brainlesion Workshop, BrainLes 2017, as well as the International Multimodal Brain Tumor Segmentation, BraTS, and White Matter Hyperintensities, WMH, segmentation challenges, which were held jointly at the Medical Image computing for Computer Assisted Intervention Conference, MICCAI, in Quebec City, Canada, in September 2017. The 40 papers presented in this volume were carefully reviewed and selected from 46 submissions. They were organized in topical sections named: brain lesion image analysis; brain tumor image segmentation; and ischemic stroke lesion image segmentation.

Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating disease and explore new areas to find successful therapeutic strategies. Various approaches such as sophisticated imaging techniques, improved surgical procedures, ground-breaking strategies for radiotherapy, chemotherapy, immunotherapy, chemoimmunotherapy, and photodynamic therapy are being used for eradicating glioblastoma. Hopefully, this book will be an important source of information on glioblastoma and therefore be highly useful to the students, postdoctoral fellows, principal investigators, and clinicians involved in this field.

This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology.

Treatment of patients with intracranial gliomas, especially high-grade neoplasms, usually requires postoperative adjuvant therapy. Significant progress in the understanding of tumor biology, technological advances in irradiation delivery, and development of novel antitumor drugs have led to an expansion of the therapeutic arsenal in neuro-oncology. This publication provides a unique review of the various options for adjuvant therapy. Special emphasis is on current evidence-based treatment standards and guidelines, and on perspectives of further improvement in long-term outcomes. Chapters review the histopathological and molecular features of gliomas and describe basic principles and clinical results of fractionated radiotherapy, stereotactic radiosurgery, brachytherapy, use of radiosensitizers, systemic chemotherapy and antiangiogenic therapy. Particular attention is paid to treatment of pediatric patients and to physical and psychological rehabilitation and supportive care at the end of life. This book and its accompanying volumes are mainly directed at neuro-oncologists, radiation oncologists, and other clinicians treating patients with brain tumors.

This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. The management of patients with high-grade gliomas has historically been one of the most challenging and disheartening fields in medicine, where failure is the rule and longevity is the exception. The jaded often state that despite purported advances in surgical and radiotherapeutic techniques and a myriad of clinical trials of medical therapies, the s- vival statistics for glioblastoma have not changed in the last three decades. The nihilism associated with these tumors is such that some practitioners still advise against treatment or even biopsy, recommending palliative care with the diagnosis based only on history and an MRI scan. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject. The fact is that we have recently entered an era where real progress is being made in our understanding and treatment of high-grade gliomas that is directly benefiting some patients. We are slowly but surely chipping away at this problem. One approach has exploited correlations between particular molecular markers and therapeutic response. The first such “breakthrough” in high-grade glioma was the observation that loss of chromosomes 1p and 19q uniformly predict chemosensitivity in anaplastic oligodendrogliomas (1).